The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
 
Debashis Sarker
Honoraria - Bayer; Ipsen; Pfizer; Pfizer (I)
Consulting or Advisory Role - Baxalta; Blueprint Medicines; Eisai; Eisai (I); Ipsen (I); Novartis
Travel, Accommodations, Expenses - Bayer; ipsen; MiNA Therapeutics
 
Elizabeth Ruth Plummer
Honoraria - Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Clovis Oncology; Modulatex; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Bristi Basu
Consulting or Advisory Role - Astex Pharmaceuticals (Inst); Baxter; Celgene (Inst)
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer Health
 
Tim Meyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Kai-Wen Huang
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Eisai
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Eisai; Karus Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Eisai
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Sierra Oncology (Inst); Verastem (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Duncan Spalding
No Relationships to Disclose
 
Yuk Ting Ma
Honoraria - Bayer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Bayer
 
Daniel H. Palmer
Honoraria - Bayer; Bristol-Myers Squibb; Celgene; Nucana
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Nucana
Research Funding - Bayer; Nucana
 
Cheng Ean Chee
Consulting or Advisory Role - Bayer
 
Nagy A Habib
Leadership - MiNA therapeutics
Stock and Other Ownership Interests - MiNA Therapeutics
Research Funding - MiNA therapeutics
Travel, Accommodations, Expenses - MiNA Therapeutics